Lupin Pharmaceuticals has launched calcium acetate capsules, used to treat hyperphosphatemia in end stage renal failure, in the United States after receiving approval from the Food and Drug Administration (FDA).
Lupin Pharmaceuticals Inc, a subsidiary of the company, has launched calcium acetate capsules having received final approval from the US health regulator, the company said in a statement.
‘Lupin has launched calcium acetate capsules having received final approval from the US health regulator.’
The Mumbai-based firm's product is the generic version of Fresenius Medical Care North America's PhosLo Gelcaps.
The drug is indicated for the control of hyperphosphatemia in end stage renal failure.
As per IMS sales data, PhosLo Gelcaps had annual US sales of $54.5 million.
Shares in Lupin, on October 26, ended 1.25 percent lower at Rs. 2,053.40 apiece on the BSE, whose benchmark Sensex index finished down 0.4 percent.